Jump to content

Aleixo Muise

Add links
From Wikipedia, the free encyclopedia
Aleixo Muise
Born (1969-06-05) June 5, 1969 (age 55)
NationalityCanadian
Alma mater
Known for
Scientific career
Fields
Institutions

Aleixo M. Muise FRCPC (born June 5, 1969) is a Canadian scientist, pediatrician and gastroenterologist known for contributions to the understanding of very early onset inflammatory bowel disease. He is a professor of pediatrics at the University of Toronto, a Tier 1 Canada Research Chair in pediatric inflammatory bowel disease, and a pediatric gastroenterologist at the Hospital for Sick Children.

Biography

[edit]

Muise completed a Bachelor of Science degree at St. Francis Xavier University, followed by graduate studies at Carleton University and Dalhousie University.[1] His postgraduate work was with Daniela Rotin at the Hospital for Sick Children in Toronto.[1] He completed undergraduate and postgraduate training in medicine, pediatrics and gastroenterology at the University of Toronto.[1]

Muise was appointed as full professor in the departments of Pediatrics and Biochemistry and in the Institute of Medical Science at the University of Toronto in 2018.[1] He was awarded a Tier 1 Canada Research Chair in pediatric inflammatory bowel disease in 2019.[2]

Research

[edit]

Muise's clinical and research program focuses on very early onset inflammatory bowel disease (VEOIBD), a type of inflammatory bowel disease that affects children under the age of six. His research program has identified a number of novel genetic determinants in IBD and VEOIBD. Muise's laboratory uses techniques such as whole exome sequencing and whole genome sequencing to identify known and novel genetic variants in children with intestinal diseases. Most notably, Muise identified a novel form of VEOIBD related to mutations in the TTC7A gene[3] and described potential treatments for this incurable disease.[4] He has uncovered the underlying genetic and functional causes of a number of diseases, including PLVAP, ARPC1B and SYK.[5][6][7]

Muise's research has allowed for appropriate, personalized treatment to be given to children with genetic forms of intestinal disease, including bone marrow transplantation.[8][9] Muise's lab has also identified VEOIBD rare functional variants in the NADPH oxidase genes, iNOS, and IL10R that lead to risk of developing VEOIBD, and may allow for novel treatment strategies based on these genetic findings.[10]

Muise founded the interNational Early Onset Paediatric IBD Cohort Study (NEOPICS) consortium, which connects pediatric gastroenterologists and scientists internationally to identify patients with rare intestinal diseases. This has allowed for the creation of the largest repository of DNA of patients with VEOIBD.[11]

Honors

[edit]

References

[edit]
  1. ^ a b c d "Aleixo Muise". Hospital for Sick Children (Toronto). Retrieved May 11, 2021.
  2. ^ a b "Canada Research Chairs Spring 2019 Recipients (Cycle 2018-2)". Government of Canada. 2020-02-26. Retrieved May 12, 2021.
  3. ^ Avitzur, Yaron; Guo, Conghui; Mastropaolo, Lucas A.; Bahrami, Ehsan; Chen, Hannah; Zhao, Zhen; Elkadri, Abdul; Dhillon, Sandeep; Murchie, Ryan; Fattouh, Ramzi; Huynh, Hien; Walker, Jennifer L.; Wales, Paul W.; Cutz, Ernest; Kakuta, Yoichi; Dudley, Joel; Kammermeier, Jochen; Powrie, Fiona; Shah, Neil; Walz, Christoph; Nathrath, Michaela; Kotlarz, Daniel; Puchaka, Jacek; Krieger, Jonathan R.; Racek, Tomas; Kirchner, Thomas; Walters, Thomas D.; Brumell, John H.; Griffiths, Anne M.; Rezaei, Nima; Rashtian, Parisa; Najafi, Mehri; Monajemzadeh, Maryam; Pelsue, Stephen; McGovern, Dermot P.B.; Uhlig, Holm H.; Schadt, Eric; Klein, Christoph; Snapper, Scott B.; Muise, Aleixo M. (2014). "Mutations in Tetratricopeptide Repeat Domain 7A Result in a Severe Form of Very Early Onset Inflammatory Bowel Disease". Gastroenterology. 146 (4). Elsevier BV: 1028–1039. doi:10.1053/j.gastro.2014.01.015. ISSN 0016-5085. PMC 4002656. PMID 24417819.
  4. ^ Jardine, Sasha; Anderson, Sierra; Babcock, Stephen; Leung, Gabriella; Pan, Jie; Dhingani, Neel; Warner, Neil; Guo, Conghui; Siddiqui, Iram; Kotlarz, Daniel; Dowling, James J.; Melnyk, Roman A.; Snapper, Scott B.; Klein, Christoph; Thiagarajah, Jay R.; Muise, Aleixo M. (2020). "Drug Screen Identifies Leflunomide for Treatment of Inflammatory Bowel Disease Caused by TTC7A Deficiency". Gastroenterology. 158 (4). Elsevier BV: 1000–1015. doi:10.1053/j.gastro.2019.11.019. ISSN 0016-5085. PMC 7062591. PMID 31743734.
  5. ^ Elkadri, Abdul; Thoeni, Cornelia; Deharvengt, Sophie J.; Murchie, Ryan; Guo, Conghui; Stavropoulos, James D.; Marshall, Christian R.; Wales, Paul; Bandsma, Robert H.J.; Cutz, Ernest; Roifman, Chaim M.; Chitayat, David; Avitzur, Yaron; Stan, Radu V.; Muise, Aleixo M. (2015). "Mutations in Plasmalemma Vesicle Associated Protein Result in Sieving Protein-Losing Enteropathy Characterized by Hypoproteinemia, Hypoalbuminemia, and Hypertriglyceridemia". Cellular and Molecular Gastroenterology and Hepatology. 1 (4): 381–394.e7. doi:10.1016/j.jcmgh.2015.05.001. ISSN 2352-345X. PMC 4507283. PMID 26207260.
  6. ^ Kahr, Walter H. A.; Pluthero, Fred G.; Elkadri, Abdul; Warner, Neil; Drobac, Marko; Chen, Chang Hua; Lo, Richard W.; Li, Ling; Li, Ren; Li, Qi; Thoeni, Cornelia; Pan, Jie; Leung, Gabriella; Lara-Corrales, Irene; Murchie, Ryan; Cutz, Ernest; Laxer, Ronald M.; Upton, Julia; Roifman, Chaim M.; Yeung, Rae S. M.; Brumell, John H; Muise, Aleixo M (2017). "Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease". Nature Communications. 8 (1). Springer Science and Business Media LLC: 14816. Bibcode:2017NatCo...814816K. doi:10.1038/ncomms14816. ISSN 2041-1723. PMC 5382316. PMID 28368018.
  7. ^ Wang, Lin; Aschenbrenner, Dominik; Zeng, Zhiyang; Cao, Xiya; Mayr, Daniel; Mehta, Meera; Capitani, Melania; Warner, Neil; Pan, Jie; Wang, Liren; Li, Qi; Zuo, Tao; Cohen-Kedar, Sarit; Lu, Jiawei; Ardy, Rico Chandra; Mulder, Daniel J.; Dissanayake, Dilan; Peng, Kaiyue; Huang, Zhiheng; Li, Xiaoqin; Wang, Yuesheng; Wang, Xiaobing; Li, Shuchao; Bullers, Samuel; Gammage, Anís N.; Warnatz, Klaus; Schiefer, Ana-Iris; Krivan, Gergely; Goda, Vera; Kahr, Walter H. A.; Lemaire, Mathieu; Lu, Chien-Yi; Siddiqui, Iram; Surette, Michael G.; Kotlarz, Daniel; Engelhardt, Karin R.; Griffin, Helen R.; Rottapel, Robert; Decaluwe, Hélène; Laxer, Ronald M.; Proietti, Michele; Hambleton, Sophie; Elcombe, Suzanne; Guo, Cong-Hui; Grimbacher, Bodo; Dotan, Iris; Ng, Siew C.; Freeman, Spencer A.; Snapper, Scott B.; Klein, Christoph; Boztug, Kaan; Huang, Ying; Li, Dali; Uhlig, Holm H.; Muise, Aleixo M. (2021-03-29). "Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice". Nature Genetics. 53 (4). Springer Science and Business Media LLC: 500–510. doi:10.1038/s41588-021-00803-4. ISSN 1061-4036. PMC 8245161. PMID 33782605.
  8. ^ Picard, Andre (10 December 2012). "Bone-marrow transplant cures girl's inflammatory bowel disease". The Globe and Mail. Toronto.
  9. ^ Ubelacker, Sheryl (3 April 2017). "Toronto doctors identify new disease in children caused by defective gene". Canadian Press. Toronto.
  10. ^ a b Jung, Barbara (2015). "GRG President's Report". Digestive Diseases and Sciences. 60 (10): 2853–2854. doi:10.1007/s10620-015-3849-8. ISSN 0163-2116. PMID 26289262.
  11. ^ "NEOPICS". Retrieved May 10, 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Aleixo_Muise&oldid=1231293164"